Research institution
Henan Cancer Hospital Clinical Trials
Studies where Henan Cancer Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 96Locally Advanced Resectable Rectal Cancer
Exploratory Study of Short-Course Radiotherapy Followed by Adebrelimab Combined With Chemotherapy for Organ Preservation in Locally Advanced Rectal Cancer
This prospective, single-arm, exploratory clinical study aims to evaluate the efficacy and safety of short-course radiotherapy (SCRT) sequentially followed by adebrelimab combined with chemotherapy as an organ-preservation…
- Trial name
- NCT07905950
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer
In recent years, the successful application of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has transformed the treatment landscape for HR+/HER2- advanced breast cancer and driven research into their use in adjuvant settings.
- Trial name
- NCT07706933
- Testing
- Dalpiciclib, Abemaciclib/Ribociclib
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
HR+/HER2- Breast Cancer
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens.
- Trial name
- NCT06860529
- Testing
- Serplulimab, Epirubicin, Albumin Paclitaxel
- Where
- China
- Volunteers
- 357 people
- Sponsor
- Henan Cancer Hospital
Advanced Breast Cancer
Exploring Curative Model for Advanced Breast Cancer: a Single-center, Prospective Phase II Clinical Study
To explore the duration of continued treatment for patients with advanced breast cancer who achieve complete response assessed by PET-CT after receiving systemic anti-tumor therapy.
- Trial name
- NCT07888556
- Where
- China
- Volunteers
- 147 people
- Sponsor
- Henan Cancer Hospital
HER2-positive, Metastatic Breast Cancer
ARX788 in HER2-positive Metastatic Breast Cancer Patients
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
- Trial name
- NCT06663748
- Testing
- ARX788
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Henan Cancer Hospital
Breast Cancer
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of anlotinib combined with vinorelbine in the treatment of HER2- advanced breast cancer.
- Trial name
- NCT05296577
- Testing
- anlotinib and vinorelbine, Vinorelbine injection
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Henan Cancer Hospital
Advanced Breast Cancer
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer
This study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 in advanced breast cancer.
- Trial name
- NCT07125950
- Testing
- SHR2554, HRS-8080
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Metastatic Breast Cancer
A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined With Capecitabine in the Treatment of Active Brain Metastasis of TNBC
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment…
- Trial name
- NCT06598046
- Testing
- Utidelone and capecitabine
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Henan Cancer Hospital
HER2-positive Advanced Breast Cancer, Brain Metastases
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
A total of 224 subjects of HER2-positive advanced breast cancer with brain metastases are planned to be enrolled. Eligible subjects will be randomly assigned in a 1:1 ratio to the group receiving Trastuzumab Rezetecan combined…
- Conditions
- HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
- Trial name
- NCT07100600
- Testing
- Trastuzumab Rezetecan, FSRT or WBRT
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Henan Cancer Hospital
GC, GEJC
Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure
Using a prospective, exploratory trial design, we aim to evaluate the efficacy and safety of RC-Trastuzumab combined with Rilafup Alpha in treating first-line systemically treated HER2（Human Epidermal Growth Factor Receptor 2 ）…
- Trial name
- NCT07817654
- Testing
- Trastuzumab Rezetecan+Retlirafusp alfa
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Henan Cancer Hospital